Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B14 | Q9BPX1 | 4/20 | 0.57 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.50 |
| ▸ | CNR2 | P34972 | 3/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179891 | 0.87 | HSD17B1 (0.47) | HSD17B14HSD17B1HSD17B2CNR2ABL1 | |
| SCHEMBL483444 | 0.84 | MAPT (0.56) | HSD17B14HSD17B1HSD17B2CYP1A2GAA | |
| SCHEMBL1260197 | 0.84 | ALDH1A1 (0.52) | CNR2GAARAB9ASMN1; SMN2FAAH | |
| SCHEMBL31507571 | 0.84 | CNR2 (0.46) | CNR2CYP1A2GAAMAPTRECQL | |
| SCHEMBL19899368 | 0.84 | CNR2 (0.46) | CNR2CYP1A2GAAMAPTRECQL | |
| SCHEMBL4592907 | 0.84 | CNR2 (0.65) | CNR2 | |
| SCHEMBL6439408 | 0.84 | MAPT (0.55) | CNR2CYP1A2GAAMAPTRECQL | |
| SCHEMBL20929247 | 0.82 | TRPV3 (0.47) | CNR2CYP1A2GAAMAPTRECQL | |
| SCHEMBL23037197 | 0.82 | MAPT (0.54) | CYP1A2GAAMAPTRECQLNPC1 | |
| SCHEMBL29595815 | 0.82 | MAPT (0.54) | CYP1A2GAAMAPTRECQLNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703700-B2 | Bimacrocylic HCV NS3 protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2432318-A1 | BIMACROCYCLIC HCV NS3 PROTEASE INHIBITORS | Sequoia Pharmaceuticals, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010135748-A1 | BIMACROCYCLIC HCV NS3 PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010135748-A1 | BIMACROCYCLIC HCV NS3 PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | HAVCR2, CTRC, CTSC | HSD17B14 900/4885HSD17B1 2143/4885HSD17B2 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.